Search Results - "Johnson, B.E"

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy by Nishino, M, Jackman, D.M, DiPiro, P.J, Hatabu, H, Jänne, P.A, Johnson, B.E

“…Aim To revisit the presumed relationship between tumour diameter and volume in advanced non-small-cell lung cancer (NSCLC) patients, and determine whether the…”
Get full text

Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC) by Parikh, R.B, Cronin, A, Kozono, D.E, Oxnard, G.R, Mak, R.H, Jackman, D.M, Lo, P.C, Baldini, E.H, Johnson, B.E, Chen, A.B

Get full text

An Assessment of Jejunostomy Tube Placement in Patients Undergoing Pancreaticoduodenectomy for Adenocarcinoma: Routine Placement is not Justified by Johnson, B.E, Cyr, A.R, Button, A.M, Hoshi, H, Howe, J.R, Mezhir, J.J

Get full text

Sarcopenia Predicts Operative Complications Following Pancreatectomy for Adenocarcinoma by Joglekar, S, Asghar, A, Johnson, B.E, Bell, S, Button, A, Palakodeti, A, Rajput, M, Howe, J.R, Mezhir, J.J

Get full text

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC) by Johnson, B.E, Kris, M.G, Kwiatkowski, D.J, Wistuba, I.I, Engelman, J.A, Pao, W, Rudin, C.M, Berry, L, Minna, J.D, Bunn, P.A

Get full text

Cancer Research and Clinical Oncology for the Next Decade by Johnson, B.E.

Get full text

P79 Assessing the utility of matrix-degrading enzymes as a biomarker for disease status and therapeutic efficacy in lung cancer by Gandhi, L, Exarhopoulos, A, Johnson, B.E, Moses, M.A

Get full text

Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis by George, S A, Bilsland, D J, Johnson, B E, Ferguson, J

“…In an open study of 21 severely affected adult atopic dermatitis patients, air-conditioned narrow-band UVB phototherapy using the Philips TL-01 lamp three…”
Get more information

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial by Eberhardt, W.E.E, Johnson, B.E, Sun, Y, Germonpré, P, Saijo, N, Zhou, C, Wang, J, Tada, H, Kennedy, S.J, Herbst, R.S

Get full text

NAUTIKA1: A Multicenter Phase II Study with a PD-L1+ Cohort of Patients Receiving Atezolizumab (Atezo) with Low-Dose Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant Therapy for Resectable Stage IB-III NSCLC by Tian, S., Kozono, D.E., Ohri, N., Jolly, S., Johnson, B.E., Chaft, J., Toloza, E.M., Ding, B., Ngiam, C., Schulz, K., Bara, I., Lee, J.M.

Get full text

311 nm UVB phototherapy--an effective treatment for psoriasis by Green, C, Ferguson, J, Lakshmipathi, T, Johnson, B E

“…Fifty two psoriatic patients were treated with a new experimental fluorescent lamp (Philips TL-01) emitting a narrow band at 311 +/- 2 nm (UVB) which had the…”
Get more information

A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption by Bilsland, D, George, S A, Gibbs, N K, Aitchison, T, Johnson, B E, Ferguson, J

“…Twenty-five patients suffering from severe polymorphic light eruption (PLE) were randomized to either photochemotherapy (PUVA) or narrow-band phototherapy…”
Get more information

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC by Kris, M.G., Grindheim, J.M., Chaft, J.E., Lee, J.M., Johnson, B.E., Rusch, V.W., Bunn, P.A., Pass, H., Schum, E., Carlisle, J., Weyant, M., Nicholas, A., Johnson, A., Shames, D., Wistuba, I.I., Carbone, D.P., Schulze, K., Kwiatkowski, D.J.

Get full text

6613 POSTER Prognostic factors for radical treatment of stage III NSCLC by Allen, A.M, Othus, M, Baldini, E.H, Mentzer, S.J, Bueno, R, Sugarbaker, D.J, Colson, Y.L, Marcoux, J.P, Johnson, B.E, Caglar, H.B

Get full text

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study by Bakouny, Z, Labaki, C, Bhalla, S, Schmidt, A L, Steinharter, J A, Cocco, J, Tremblay, D A, Awad, M M, Kessler, A, Haddad, R I, Evans, M, Busser, F, Wotman, M, Curran, C R, Zimmerman, B S, Bouchard, G, Jun, T, Nuzzo, P V, Qin, Q, Hirsch, L, Feld, J, Kelleher, K M, Seidman, D, Huang, H, Anderson-Keightly, H M, El Zarif, T, Alaiwi, S Abou, Champagne, C, Rosenbloom, T D, Stewart, P S, Johnson, B E, Trinh, Q, Tolaney, S M, Galsky, M D, Choueiri, T K, Doroshow, D B

“…COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are…”
Get full text

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC by Tan, D.S.W., Kim, T.M., Solomon, B.J., Tan, W.L., Yu, C.-J., Geater, S., De Castro, G., Greystoke, A., Felip, E., Johnson, B.E., Deudon, S., Louveau, A.-L., Passos, V.Q., Cho, B.C.

Get full text

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer by Besse, B., Leighl, N., Bennouna, J., Papadimitrakopoulou, V.A., Blais, N., Traynor, A.M., Soria, J.-C., Gogov, S., Miller, N., Jehl, V., Johnson, B.E.

“…Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced…”
Get full text

Ciprofloxacin-induced photosensitivity: in vitro and in vivo studies by Ferguson, J, Johnson, B E

“…Ciprofloxacin is one of the new series of broad-spectrum antibiotic quinolones, chemically related to nalidixic acid and which may, therefore, induce…”
Get more information

Neighborhood covenants and restrictions: an examination of fit by Johnson, Brian Edward

“…Covenants and restrictions (C&Rs) have increased in popularity in recent decades, being commonly applied in new residential developments. Despite the fact that…”
Get full text

Nature, Affordability, and Privacy as Motivations for Exurban Living by Johnson, Brian Edward

“…Current demographic trends indicate that the 21st century will be one of exurban growth as more Americans seek out countryside home sites and their…”
Get full text